

Antenatal betamethasone doesn't impact pediatric bone mass

April 7 2017



(HealthDay)—Exposure to repeat doses of antenatal betamethasone is

not associated with alterations in bone mass in mid-childhood compared with a single course of glucocorticoids, according to a study published online April 7 in *Pediatrics*.

Christopher J.D. McKinlay, Ph.D., from the University of Auckland in New Zealand, and colleagues randomized women at risk for [preterm birth](#) to a single dose of betamethasone or placebo at seven or more days after an initial course of glucocorticoids, repeated each week that they remained at risk. Children were assessed with whole-body dual-energy radiograph absorption at a corrected age of 6 to 8 years. One hundred eighty-five of 212 eligible childhood survivors were assessed (91 repeat betamethasone group; 94 [placebo group](#)).

The researchers found that whole-body bone mineral content was similar for children exposed to repeat antenatal betamethasone and those exposed to placebo (553 and 567 g, respectively; geometric mean ratio, 0.99; 95 percent confidence interval, 0.94 to 1.03; $P = 0.55$), as was bone area (832 and 822 cm², respectively; geometric mean ratio, 0.99; 95 percent confidence interval, 0.92 to 1.07; $P = 0.75$).

"Exposure to repeat doses of antenatal betamethasone compared with a single course of glucocorticoids does not alter [bone mass](#) in mid-childhood," the authors write.

More information: [Abstract/Full Text \(subscription or payment may be required\)](#)

Copyright © 2017 [HealthDay](#). All rights reserved.

Citation: Antenatal betamethasone doesn't impact pediatric bone mass (2017, April 7) retrieved 10 May 2024 from <https://medicalxpress.com/news/2017-04-antenatal-betamethasone-doesnt-impact-pediatric.html>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.